# Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome

> **NCT06518005** · PHASE2 · RECRUITING · sponsor: **Genethon** · enrollment: 3 (estimated)

## Conditions studied

- Crigler-Najjar Syndrome

## Interventions

- **DRUG:** Imlifidase
- **DRUG:** GNT0003

## Key facts

- **NCT ID:** NCT06518005
- **Lead sponsor:** Genethon
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-08
- **Primary completion:** 2026-09-30
- **Final completion:** 2030-09-30
- **Target enrollment:** 3 (ESTIMATED)
- **Last updated:** 2024-12-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06518005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06518005, "Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06518005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*